BIT Capital GmbH Has $125.37 Million Stock Holdings in Hims & Hers Health, Inc. $HIMS

BIT Capital GmbH lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 73.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,210,384 shares of the company’s stock after purchasing an additional 938,728 shares during the quarter. Hims & Hers Health accounts for 4.2% of BIT Capital GmbH’s holdings, making the stock its 6th largest position. BIT Capital GmbH owned 0.98% of Hims & Hers Health worth $125,373,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in Hims & Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after acquiring an additional 200 shares during the period. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 6.1% during the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after purchasing an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC increased its position in shares of Hims & Hers Health by 1.8% in the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after purchasing an additional 252 shares during the period. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares in the last quarter. Finally, Bessemer Group Inc. raised its stake in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares in the company, valued at $226,684.25. This trade represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $6,238,497.40. The trade was a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 82,963 shares of company stock valued at $2,944,621 over the last three months. Insiders own 13.71% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $15.83 on Friday. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The stock has a market cap of $3.60 billion, a PE ratio of 29.31, a PEG ratio of 2.96 and a beta of 2.43. Hims & Hers Health, Inc. has a 12-month low of $15.46 and a 12-month high of $70.43. The business has a 50-day simple moving average of $29.06 and a two-hundred day simple moving average of $40.78.

Hims & Hers Health announced that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to buy up to 3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Citigroup lowered their price objective on shares of Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a research report on Monday, February 9th. Evercore initiated coverage on Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, Bank of America dropped their price objective on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $39.32.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Announced acquisition of Australian digital‑health provider Eucalyptus for up to $1.15 billion to accelerate international expansion and broaden personalized‑care offerings; management says the deal builds scale in a new market. Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
• Positive Sentiment: Analysts and press point to meaningful revenue upside from Eucalyptus (reported ~ $450M in annual revenue and rapid growth) and the deal briefly lifted sentiment / shares after the announcement. This supports the company’s strategy to find new growth engines beyond its core U.S. franchises. Hims & Hers HUGE Acquisition News!
• Neutral Sentiment: Deal size and funding: the acquisition is material (up to $1.15B); using significant cash or financing could affect liquidity and leverage—investors should watch financing details and integration execution. Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint
• Neutral Sentiment: Context on valuation and technicals: HIMS remains well below its 50‑ and 200‑day moving averages and near its 1‑year low, with a market cap and leverage profile investors should weigh when sizing positions. HIMS MarketBeat profile
• Negative Sentiment: Regulatory and industry backlash over the company’s copycat GLP‑1 weight‑loss pills: reporting shows Novo Nordisk and U.S. regulators pushed back, and Reuters/others say the GLP‑1 pivot has accelerated scrutiny of drug compounders — a development that can hit sales, raise compliance costs and damage trust. Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
• Negative Sentiment: Legal and analyst pressure: a shareholder investigation has been announced and some analysts cite near‑term growth concerns and lowered price targets after the GLP‑1 launch reversal — factors that could weigh on the stock and raise the risk premium. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.